Progyny Q2 revenue $279.4M (+43% YoY); raises full-year guidance

Progyny, Inc.

2023-Q2 EPS reported $330.00 revenue$279,373,000

Revenue $279.4M (+43% YoY); net income $15.0M ($0.15 diluted EPS) vs $8.8M ($0.09) YoY.
Adjusted EBITDA $47.5M (+44% YoY); record operating cash flow $76.0M, helped by new pharmacy partner agreements.
Clients grew to 384 (from 273); ART cycles 14,771 (+42% YoY); utilization rates improved.
FY 2023 revenue guidance raised to $1,075-1,090M (37-39% growth); adj EBITDA guided $183-187.5M.
Q3 2023 revenue guided $268-273M; adj EBITDA $44.7-46.2M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Progyny, Inc. reported three-month period ended June 30, 2023 results: revenue $279,373, net income $14,991, EPS $0.15. Guidance raised.

Period: three-month period ended June 30, 2023
Revenue: $279,373
Net income: $14,991
EPS: $0.15
Guidance: raised
Result: reported results

Exact text from the filing

quarter,” said Mark Livingston, Progyny’s Chief Financial Officer. Second Quarter 2023 Highlights: (unaudited; in thousands, except per share amounts) 2Q 2023 2Q 2022 Revenue $279,373 $195,004 Gross Profit $60,641 $43,887 Gross Margin 21.7% 22.5% Net Income $14,991 $8,768 Net Income per Diluted Share 1 $0.15 $0.09 Adjusted EBITDA 2 $47,464 $32,878 Adjusted

View on SEC.gov

Browse all earnings releases →

Progyny, Inc. filing history →

Source: SEC EDGAR

accession 0001551306-23-000060

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.